New acromegaly therapy watch: Camurus’ Sonnie Kim on the monthly octreotide pen

We ran into Sonnie Kim, Camurus’ head of Medical Affairs, at this year’s ENDO2026 conference in Chicago and asked her about the latest on CAM2029, the long-acting octreotide subcutaneous depot delivered by a pre-filled pen, built on the company’s FluidCrystal technology. The product is approved in Europe under the brand name Oczyesa  and is still awaiting US approval.

CAM2029 is a subcutaneous long-acting octreotide depot using FluidCrystal technology, designed for once-monthly self-administration via an autoinjector pen, with roughly five-fold higher bioavailability than long-acting IM octreotide, and Phase 3 ACROINNOVA results showing superior biochemical control versus placebo plus improvements in symptom control, treatment satisfaction, and quality of life against baseline standard of care.  If you want to learn more, listen to this podcast with Dr. Joanna Spencer-Segal, also recorded at this year’s ENDO conference.  As we’ve reported, CAM2029 is built on Camurus’ FluidCrystal technology, a lipid-based delivery system that forms a depot under the skin and releases octreotide slowly over the course of a month. Click here to listen to Dr. Markus Johnsson, Senior VP of R&D at Camurus, explaining FluidCrystal technology.  

Editor’s Note: The U.S. approval path for CAM 2029 (Oclaiz™) is moving, but not there yet. An FDA Complete Response Letter in June 2026 concerned a manufacturing-site inspection, not safety or efficacy. The resubmission was accepted for review in July, with a decision expected by December 18, 2026.  The practical consequences for patients are a much smaller, subcutaneous injection that patients can give themselves with a pre-filled pen, and, importantly, more treatment options.  Practically, this means more chances that a therapy actually fits a patient’s life.  Stay tuned!